<DOC>
	<DOCNO>NCT00687648</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , methotrexate , prednisolone , work different way stop growth tumor cell , either kill cell stop dividing . Estrogen cause growth breast cancer cell . Hormone therapy use anastrozole , letrozole , exemestane may fight breast cancer lower amount estrogen body make . It yet know whether give combination chemotherapy together aromatase inhibitor therapy effective combination chemotherapy alone treat breast cancer . PURPOSE : This randomized phase II trial study give cyclophosphamide , methotrexate , prednisolone together aromatase inhibitor therapy see well work compare cyclophosphamide , methotrexate , prednisolone treat postmenopausal woman metastatic breast cancer .</brief_summary>
	<brief_title>Cyclophosphamide , Methotrexate , Prednisolone With Without Aromatase Inhibitor Therapy Treating Postmenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare clinical benefit rate ( complete response , partial response stable disease &gt; 24 week ) postmenopausal woman metastatic breast cancer treat metronomic chemotherapy v without aromatase inhibitor therapy . Secondary - Compare time progression patient - Compare overall survival patient . - Compare safety toxicity regimens patient . - Correlate tumor response marker angiogenesis ( circulate endothelial progenitor cell , VEGF , VEGF-C , VEGFR-2 , VEGFR-3 ) . - Determine relative contribution methotrexate prednisolone metronomic chemotherapy assess change circulate endothelial progenitor cell , VEGF , VEGFR level serial addition drug . OUTLINE : Patients stratify accord site metastasis ( visceral v non-visceral ) number line prior chemotherapy metastatic setting ( 0 vs 1-2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive aromatase inhibitor ( anastrozole , letrozole , exemestane ) previously prescribe . Patients also receive oral cyclophosphamide daily day 1-28 oral methotrexate twice day 15 , 16 , 22 , 23 course 1 . For subsequent course , patient receive oral cyclophosphamide daily oral prednisolone daily day 1-28 oral methotrexate twice day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 . Treatment cyclophosphamide , methotrexate , prednisolone repeat every 28 day absence disease progression unacceptable toxicity . - Arm II : Patients receive cyclophosphamide , methotrexate , prednisolone arm I . Patients undergo blood sample collection baseline , week 2 , 4 , 6 , 10 , every 4 week disease progression , 4 week disease progression . Blood sample assess circulate endothelial progenitor cell level flow cytometry VEGF , VEGF-C , VEGFR-2 , VEGFR-3 level ELISA immunoassay . After completion study therapy , patient follow every 3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer Metastatic disease Measurable disease , define RECIST criterion Evidence disease progression receive thirdgeneration aromatase inhibitor No extensive visceral disease ( &gt; 50 % liver lung parenchymal involvement ) No pleural effusion ascites No HER2/neu overexpression Hormone receptor status : Estrogen receptor progesterone receptorpositive tumor PATIENT CHARACTERISTICS : Postmenopausal , define follow : Over 60 year age 5059 year age plasma folliclestimulating hormone , luteinizing hormone , estradiol postmenopausal range amenorrhea &gt; 1 year Any age document bilateral oophorectomy ECOG performance status ( PS ) 02 ( Karnofsky PS 60100 % ) Life expectancy &gt; 6 month Leukocytes ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Total bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant Fertile patient must use effective contraception No prior malignancy except curatively treat basal cell carcinoma skin carcinoma situ cervix No history allergic reaction attribute compound similar chemical biologic composition cyclophosphamide , methotrexate , prednisolone , anastrozole , letrozole , exemestane No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : No 2 line prior chemotherapy endocrine therapy advance disease No concurrent chemotherapy , immunotherapy , anticancer hormonal therapy , anticancer surgery No concurrent anticancer therapy No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>